It's unclear how or when the pharmaceutical industry became the new whipping boy for the press and Congress alike. Fair or unfair, this is the new reality, and since CME is largely funded by industry, we can expect the scrutiny to continue — even to intensify. Many of us are torn about how we should respond to the increasing criticism. Say too much, and we fear having the Congressional microscope turned on our own organizations. Say too little, and we fail to defend practices that improve ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.